Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
Abstract Background Glucocorticoid (GC)-induced hyperglycemia is characterized by elevated postprandial blood glucose, which commonly requires multiple insulin injections. We investigated whether a long-acting glucagon-like peptide-1 receptor agonist, dulaglutide (Dula), safely improved GC-induced h...
Main Authors: | Hiroyuki Uchinuma, Masashi Ichijo, Noriyuki Harima, Kyoichiro Tsuchiya |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12902-020-0542-5 |
Similar Items
-
Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01) -
Treatment of glucocorticoid- induced hyperglycemia in hospitalized patients - a systematic review and meta- analysis
by: Tristan Struja, et al.
Published: (2024-01-01) -
Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
by: Hwi Seung Kim, et al.
Published: (2021-11-01) -
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
by: Jung-Hwan Cho, et al.
Published: (2024-04-01) -
The Impact of Insulin Degludec on Glucocorticoid-Induced Hyperglycemia in Patients with Diabetes and COVID-19 Infection
by: Varun Prasanna, et al.
Published: (2024-04-01)